Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma.

Trial Profile

Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Pidilizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors CureTech
  • Most Recent Events

    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Apr 2013 Planned end date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top